ITMI20130127A1 - Composizione e suo uso nel trattamento delle ragadi anali - Google Patents

Composizione e suo uso nel trattamento delle ragadi anali

Info

Publication number
ITMI20130127A1
ITMI20130127A1 IT000127A ITMI20130127A ITMI20130127A1 IT MI20130127 A1 ITMI20130127 A1 IT MI20130127A1 IT 000127 A IT000127 A IT 000127A IT MI20130127 A ITMI20130127 A IT MI20130127A IT MI20130127 A1 ITMI20130127 A1 IT MI20130127A1
Authority
IT
Italy
Prior art keywords
ragadi
anal
treatment
composition
anal ragadi
Prior art date
Application number
IT000127A
Other languages
English (en)
Italian (it)
Inventor
Filippo Bastia
Maurizio Saccomanno
Original Assignee
Thd Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITMI20130127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thd Spa filed Critical Thd Spa
Priority to IT000127A priority Critical patent/ITMI20130127A1/it
Publication of ITMI20130127A1 publication Critical patent/ITMI20130127A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5775—Hibiscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT000127A 2012-01-30 2013-01-29 Composizione e suo uso nel trattamento delle ragadi anali ITMI20130127A1 (it)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT000127A ITMI20130127A1 (it) 2012-01-30 2013-01-29 Composizione e suo uso nel trattamento delle ragadi anali

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2012/000027 WO2013114410A1 (en) 2012-01-30 2012-01-30 A composition and use thereof in the treatment of anal rhagades
IT000127A ITMI20130127A1 (it) 2012-01-30 2013-01-29 Composizione e suo uso nel trattamento delle ragadi anali

Publications (1)

Publication Number Publication Date
ITMI20130127A1 true ITMI20130127A1 (it) 2013-07-31

Family

ID=46001672

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000127A ITMI20130127A1 (it) 2012-01-30 2013-01-29 Composizione e suo uso nel trattamento delle ragadi anali

Country Status (24)

Country Link
US (1) US9345747B2 (enExample)
EP (1) EP2646039B1 (enExample)
JP (1) JP5903505B2 (enExample)
KR (1) KR101599447B1 (enExample)
CN (2) CN104114177A (enExample)
AU (1) AU2012368815B2 (enExample)
BR (1) BR112014018850A8 (enExample)
CA (1) CA2863369C (enExample)
DK (1) DK2646039T3 (enExample)
ES (1) ES2485490T3 (enExample)
HR (1) HRP20140594T1 (enExample)
IL (1) IL233875A (enExample)
IN (1) IN2014MN01733A (enExample)
IT (1) ITMI20130127A1 (enExample)
MX (1) MX336204B (enExample)
PL (1) PL2646039T3 (enExample)
RS (1) RS53457B (enExample)
RU (1) RU2580622C2 (enExample)
SA (1) SA113340239B1 (enExample)
SG (1) SG11201404413UA (enExample)
SI (1) SI2646039T1 (enExample)
TW (1) TWI495476B (enExample)
WO (1) WO2013114410A1 (enExample)
ZA (1) ZA201405208B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3086863B2 (en) 2013-12-24 2023-01-11 The Procter & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
ITRM20150163A1 (it) * 2015-04-17 2016-10-17 Uniderm Farm S R L Composizioni farmaceutiche per il trattamento delle ragadi anali
US10117826B2 (en) 2016-03-31 2018-11-06 Peter Angia Pham Bodily lubricating and moisturizing compositions containing plant mucilage
US10835504B2 (en) 2018-04-18 2020-11-17 G&S Laboratories, Inc. Compositions to treat anal itch
EP3787654A4 (en) * 2018-05-02 2022-04-20 Montero Gida Sanayi Ve Ticaret Anonim Sirketi TOPICAL COMPOSITIONS FOR STRETCH MARKS ON THE SKIN
RU2771015C2 (ru) * 2020-09-25 2022-04-25 Общество с ограниченной ответственностью "ФАРМКОММ" Фармацевтическая композиция в виде мази для лечения геморроя

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
KR20010006358A (ko) * 1997-04-16 2001-01-26 라보라또아레 세로비오로지끄 (소시에떼 아노님) 오크라 종자에서 추출된 단백질 분획물이 화장품으로 사용되는 용도
US6379719B1 (en) * 1998-04-08 2002-04-30 Laboratories Serobiologiques (Societe Anonyme) Use of at least one protein fraction extracted from Hibiscus esculentus seeds and cosmetic composition containing such a fraction
CN1233469A (zh) * 1998-04-28 1999-11-03 王京杭 组织修复促进剂
US6956120B2 (en) * 2000-11-09 2005-10-18 Yasushi Onaka β-1.3-1.6 glucan (Aureobasidium medium)
JP2002204687A (ja) * 2000-11-09 2002-07-23 Onaka Yasushi β−1.3−1.6グルカン(アウレオバシジウム培養液)の医療、保健、福祉、食品および各種産業分野での応用
JP2003104832A (ja) * 2001-09-28 2003-04-09 Chifure Keshohin:Kk 皮膚外用剤
JP4544500B2 (ja) * 2002-07-19 2010-09-15 一丸ファルコス株式会社 ヒアルロン酸合成促進剤
CA2523021C (en) * 2003-05-02 2013-06-11 Ceapro Inc. Improved extraction and purification method for cereal beta-glucan
RU2277920C2 (ru) * 2004-02-24 2006-06-20 Государственное Учреждение "Пятигорский Государственный Научно-Исследовательский Институт Курортологии Министерства Здравоохранения Российской Федерации" Способ лечения детей, больных хроническим вирусным гепатитом, с применением сульфидных ванн и слабоуглекислой минеральной водой
ITMI20042111A1 (it) * 2004-11-04 2005-02-04 Biofarmitalia Spa Cerotto contenenti una sostanza scelta tra i catrami aventi caratteristiche riducenti in dermatologia
JP5048935B2 (ja) * 2005-08-24 2012-10-17 株式会社ヤクルト本社 保湿剤
DE202007004856U1 (de) * 2007-04-01 2007-06-06 Rühle, Wilfried, Dipl.-Ing. CHM Anti Aging Komplex
CN101095482B (zh) * 2007-07-05 2012-02-15 中国科学院长春应用化学研究所 制备膳食纤维食品用大麦麦麸或燕麦麦麸的制法
US20090202664A1 (en) * 2008-02-11 2009-08-13 Svetislav Mikalacki Herbal cream or oil for the treatment hemorroids and wounds
ITUD20100112A1 (it) * 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
CN102084963A (zh) * 2010-09-29 2011-06-08 吉林省农业机械研究院 一种制备燕麦麦麸膳食纤维食品的方法

Also Published As

Publication number Publication date
US20140303094A1 (en) 2014-10-09
JP5903505B2 (ja) 2016-04-13
KR101599447B1 (ko) 2016-03-14
SG11201404413UA (en) 2014-10-30
TWI495476B (zh) 2015-08-11
HK1186378A1 (en) 2014-03-14
BR112014018850A2 (enExample) 2017-06-20
PL2646039T3 (pl) 2014-10-31
HRP20140594T1 (hr) 2014-10-24
AU2012368815B2 (en) 2018-03-01
IN2014MN01733A (enExample) 2015-07-10
EP2646039B1 (en) 2014-05-14
ZA201405208B (en) 2015-10-28
BR112014018850A8 (pt) 2017-07-11
AU2012368815A1 (en) 2014-09-18
WO2013114410A1 (en) 2013-08-08
RU2014129391A (ru) 2016-03-27
SI2646039T1 (sl) 2014-10-30
CN109865000A (zh) 2019-06-11
JP2015504915A (ja) 2015-02-16
US9345747B2 (en) 2016-05-24
RU2580622C2 (ru) 2016-04-10
DK2646039T3 (da) 2014-08-11
SA113340239B1 (ar) 2015-07-07
CN104114177A (zh) 2014-10-22
TW201334787A (zh) 2013-09-01
RS53457B (sr) 2014-12-31
CA2863369A1 (en) 2013-08-08
CA2863369C (en) 2020-03-10
ES2485490T3 (es) 2014-08-13
MX336204B (es) 2016-01-11
EP2646039A1 (en) 2013-10-09
KR20140127296A (ko) 2014-11-03
MX2014009244A (es) 2015-03-19
IL233875A (en) 2017-01-31
IL233875A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
SI3067358T1 (sl) Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
SI2986304T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
IL241409B (en) Mirna biogenesis in exosomes for diagnosis and therapy
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
SI3071696T1 (sl) C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
HRP20182125T1 (hr) Adenovirus koji izražava fas-himeru i korištenje istog u metodama liječenja raka
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
SI3030519T1 (sl) Triciklične benzoksaborolne spojine in njihove uporabe
SI3838271T1 (sl) Zdravljenje povišanih ravni eozinofilcev in/ali bazofilcev
EP2802362A4 (en) LIQUID GEL CONCENTRATE COMPOSITIONS AND METHODS OF USE
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
DK3434276T3 (da) Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft
SMT201600102B (it) Tritoqualina per l’uso nel trattamento della fibrosi cistica
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
BR112016004943A2 (pt) aparelho médico e uso
EP2959015A4 (en) CHARACTERIZATION OF MOLECULES IN NANOFLUIDES
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
CR20140362A (es) Fenilimidazopirazoles sustituidos y su uso
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
BR112014026880A2 (pt) composição de sensibilização e método de uso